Novartis Ag (NVS) Non-Current Deferred Tax Liability (2017 - 2025)
Novartis Ag (NVS) has disclosed Non-Current Deferred Tax Liability for 9 consecutive years, with $3.4 billion as the latest value for Q4 2025.
- Quarterly Non-Current Deferred Tax Liability rose 40.43% to $3.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.4 billion through Dec 2025, up 40.43% year-over-year, with the annual reading at $3.4 billion for FY2025, 40.43% up from the prior year.
- Non-Current Deferred Tax Liability hit $3.4 billion in Q4 2025 for Novartis Ag, up from $2.4 billion in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.4 billion in Q4 2025 to a low of $2.2 billion in Q4 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $2.8 billion across 5 years, with a median of $2.7 billion in 2022.
- Biggest five-year swings in Non-Current Deferred Tax Liability: decreased 16.31% in 2023 and later soared 40.43% in 2025.
- Year by year, Non-Current Deferred Tax Liability stood at $3.1 billion in 2021, then fell by 12.51% to $2.7 billion in 2022, then decreased by 16.31% to $2.2 billion in 2023, then grew by 7.61% to $2.4 billion in 2024, then skyrocketed by 40.43% to $3.4 billion in 2025.
- Business Quant data shows Non-Current Deferred Tax Liability for NVS at $3.4 billion in Q4 2025, $2.4 billion in Q4 2024, and $2.2 billion in Q4 2023.